With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Business Wire3d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...
FiercePharma3d
Roche gains label expansion for eye implant Susvimo to treat diabetic macular edema
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...
Medscape21h
Eye Complications Found With Use of Semaglutide, Tirzepatide
A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...
Pharm Exec3d
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Daily2d
FDA approves ranibizumab for treating diabetic macular edema
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...
pharmaphorum2d
FDA expands label for Roche's eye disease implant Susvimo
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Medical News Today10d
What do fundus photos show in diabetic retinopathy?
Diabetic retinopathy is an eye disease that can develop in people with diabetes. Without treatment, it can lead to vision loss and blindness. Fundus photography forms part of fundoscopy ...
manilatimes3d
FDA approves Roche's Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo ...